title: Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma.
abstract: BACKGROUND
  131-I-metaiodobenzylguanidine is a radioiodinated compound selectively concentrated by cells of neuroectodermal origin, including neuroblastoma cells, for this reason it may represent a promising treatment modality for neuroblastoma in childhood. Although a potential side effect of 131-I-MIBG administration is thyroid dysfunction, relatively few data are reported about this issue.
  
  
  METHODS
  A series of 14 long term surviving patients with neuroblastoma who had been treated with 131-I-MIBG courses ranging from 2.5 to 5.5 gigabecquerels after surgical and conventional pharmacologic therapy is reported.
  
  
  RESULTS
  Twelve patients developed primary hypothyroidism that was clinically overt in 8 patients and compensated in 4 patients within 6-12 months of completion of 131-I-MIBG administration. Only in two patients was thyroid function spared. Significant correlations between the cumulative dose of 131-I-MIBG and the degree of thyroid failure were not found.
  
  
  CONCLUSIONS
  Primary hypothyroidism appears to be a common side effect in children with neuroblastoma treated with 131-I-MIBG. This finding suggests that methods to preserve thyroid function other than oral administration of iodide should be sought.
authors.affiliation: Second Division of Pediatrics, G. Gaslini Institute for Children, Genoa, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Picco
authors.forename: A
authors.initials: A
authors.lastname: Garaventa
authors.forename: F
authors.initials: F
authors.lastname: Claudiani
authors.forename: M
authors.initials: M
authors.lastname: Gattorno
authors.forename: B
authors.initials: B
authors.lastname: De Bernardi
authors.forename: C
authors.initials: C
authors.lastname: Borrone
mesh_terms: D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002648:Child; D002675:Child, Preschool; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000209:etiology*; D007457:Iodine Radioisotopes / Q000009:adverse effects*; D007462:Iodobenzenes / Q000009:adverse effects*; D009447:Neuroblastoma / Q000532:radiotherapy*; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects*; D013963:Thyroid Hormones / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D013963:Thyroid Hormones; D019797:3-Iodobenzylguanidine